Get the Stockscreener App
28.07
1.30%
0.36
After Hours:
29.21
1.14
+4.06%
Agios Pharmaceuticals Inc stock is traded at $28.07, with a volume of 973.10K.
It is up +1.30% in the last 24 hours and down -0.88% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$27.71
Open:
$27.85
24h Volume:
973.10K
Relative Volume:
0.61
Market Cap:
$1.64B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.471
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+5.65%
1M Performance:
-0.88%
6M Performance:
-20.66%
1Y Performance:
-14.45%
1-Day Range:
$27.10
$28.93
1-Week Range:
$26.04
$28.93
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.07 | 1.62B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals (AGIO) Files Automatic Mixed Securities Sh - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlight - GuruFocus
AGIO: HC Wainwright & Co. Raises Price Target to $65 with Buy Ra - GuruFocus
Truist Securities raises Agios Pharma stock price target to $39 on pipeline progress - Investing.com Canada
Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating - TipRanks
Earnings call transcript: Agios Pharm Q4 2025 sees strong revenue growth - Investing.com Canada
AGIO: Strong 2025 growth, ACTIVASE launch momentum, and key pipeline catalysts set for 2026 - TradingView
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss - ChartMill
Agios Pharmaceuticals: Q4 Earnings Snapshot - kare11.com
Agios Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Availability of AQVESME™ for Thalassemia - Quiver Quantitative
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q4 Revenue $20.0M, vs. FactSet Est of $12.1M - marketscreener.com
Press Release: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - 富途牛牛
Avoiding Lag: Real-Time Signals in (AGIO) Movement - Stock Traders Daily
Agios Pharm set to report earnings amid thalassemia drug rollout By Investing.com - Investing.com Canada
Analyst Upgrade: Is Agios Pharmaceuticals Inc stock showing strong momentumRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness - Sahm
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Agios Pharmaceuticals (AGIO): Investor Outlook On A Biotech With 30.5% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in AGIO Response - Stock Traders Daily
Bull Bear: Does ProShares Trust ProShares Ultra Energy stock benefit from AI growthTrade Analysis Report & Intraday High Probability Alerts - baoquankhu1.vn
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
Recap Report: Is Agios Pharmaceuticals Inc stock showing strong momentumDividend Hike & Low Drawdown Investment Ideas - baoquankhu1.vn
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Nigeria
Swing Trade: Is Agios Pharmaceuticals Inc stock overvalued or fairly pricedMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Summary: Does Agios Pharmaceuticals Inc have a competitive edge2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - The Manila Times
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewswire Inc.
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz
Pharma News: Will Agios Pharmaceuticals Inc face regulatory challengesWeekly Gains Report & Daily Momentum Trading Reports - baoquankhu1.vn
What is Agios Pharmaceuticals Inc.’s market positionQuarterly Growth Report & Fast Moving Trade Plans - bollywoodhelpline.com
Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst - MarketBeat
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch - Sahm
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)? - Sahm
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sectors Review: Is Agios Pharmaceuticals Inc stock influenced by commodity pricesEarnings Performance Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline - MarketBeat
Agios Pharmaceuticals outlines 2026 strategic priorities - Yahoo Finance
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):